Percutaneous coronary intervention versus medical therapy for coronary heart disease

Related Experiment Video

Updated: Oct 10, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

D J Maron1

  • 1Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, 315 MRB II, Nashville, TN 37232-6300, USA. david.maron@mcmail.vanderbilt.edu

Current Atherosclerosis Reports
|December 21, 2000
PubMed

Insights

Percutaneous coronary intervention (PCI) offers angina relief for stable coronary heart disease (CHD) patients but may increase cardiac event risk compared to medical therapy. Further research is needed to define PCI's role in CHD treatment.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Medical therapy effectively reduces myocardial infarction and death in stable coronary heart disease (CHD).
  • Limited evidence exists on the impact of percutaneous coronary intervention (PCI) on hard endpoints in stable CHD patients.

Purpose of the Study:

  • To evaluate the effectiveness of PCI compared to medical therapy in patients with stable or recently stabilized CHD.
  • To address limitations of previous trials, including small sample sizes and exclusion of high-risk subjects.

Main Methods:

  • Comparison of PCI versus medical therapy in four randomized controlled trials.
  • Analysis of outcomes including angina, exercise tolerance, and cardiac events.
  • Consideration of factors like stent use, cost-effectiveness, and risk factor intervention.

Main Results:

  • PCI improved angina and exercise tolerance compared to medical therapy.
  • Medical therapy may be preferable regarding the risk of cardiac events.
  • Previous studies were limited by small sample sizes and patient selection.

Conclusions:

  • The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial aims to clarify PCI's role in stable CHD.
  • Further investigation is required to optimize treatment strategies for stable CHD patients.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...